news aktuell GmbH

nal von minden: Did my vaccine work? New rapid test for the determination of vaccination success.

25.5.2021 11:46:53 CEST | news aktuell GmbH | Press release

Share
Am I really protected against the coronavirus now? This is a question asked by many after receiving a vaccination. The medtech company nal von minden from Moers in Germany has now developed a rapid test that can reliably detect antibodies against COVID-19 pathogens in blood. The NADAL® COVID-19 S1-NAb Test is now available all over Europe.

(Moers, Germany): “People want clarity once they been vaccinated against coronavirus: They want to know if it has worked“ says Thomas Zander, CEO of nal von minden GmbH. Depending on the particular vaccine used, the COVID-19 vaccines offer 70% or more protection from the disease – but not 100%.


If the vaccine has ‘worked’, the body produces human antibodies against the disease. “These antibodies ensure that, in the event of exposure, the disease pathogens – the coronaviruses – would be readily identified and quickly repelled. Rather like the police on alert.”

These antibodies can be found in human blood and, if present, are easily detectable. With the NADAL® COVID-19 S1-NAb Test, the process takes just a few minutes. Thomas Zander explains: “Our new rapid test for the detection of coronavirus antibodies can be carried out by your GP in the future, as the test is currently only for professional use. A tiny prick of the finger is enough. The little drop of blood is added to the accompanying test cassette, and results can be read within 15 minutes.”

The new rapid test has already been comprehensively studied in the USA and China. “In the USA and China the vaccination programmes are more progressed, so the first studies were carried out there,” says Zander. “Further quality studies at German research centres will follow shortly.” It has been confirmed that the antibody test works for all kinds of vaccines (BioNtech, AstraZeneca, Johnson&Johnson, Sinovac and Moderna).

Coronavirus vaccinations usually take place across two appointments, and the new rapid test can be carried out either two weeks after the first vaccination, or two weeks after the second, says Thomas Zander. “Those who produce an immune response following the first vaccine – which can cause, for example, mild cold-like symptoms – can first wait until after the second vaccination.” Of course, the test can also be carried out weeks or even months afterwards, as nobody yet knows how long the vaccinations protect us against coronaviruses.

Contacts

Gabriele Hellwig, info@hellwig-pr.de

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:39:09 CET | Press release

Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.

Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release

(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im

Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release

Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye